Kim Christopher, Bhatta Sumita, Cyprien Lori, Fonseca Rafael, Hernandez Rohini K
Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
DOCS Global, North Wales, PA 19454, USA.
J Bone Oncol. 2018 Dec 26;14:100215. doi: 10.1016/j.jbo.2018.100215. eCollection 2019 Feb.
Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease.
骨相关事件(SREs)是多发性骨髓瘤(MM)常见的骨并发症。然而,关于其发病率的真实世界报道较少。在本研究中,肿瘤电子健康记录数据库与行政索赔数据相链接。纳入的患者年龄≥18岁,新诊断为MM,在诊断后1个月内至少有1次门诊就诊,且诊断后有≥1年的随访。研究期间为2011年1月1日至2016年12月31日。共纳入343例患者,其中35%有任何SRE的基线病史。在中位随访25.7个月期间,34%的患者在诊断后发生了SREs。发生SRE的中位时间为167天。在发生SRE的患者中,68%在第一年内发生了SRE。有基线病史的患者在MM诊断后1年的SRE发病率为103/100人年(PY),而无基线病史的患者为16/100PY。开始一线治疗后3个月内的SRE发病率随后续治疗线数增加(第1线:81/100PY,第2线:118/100PY,第3线:150/100PY)。不同的抗MM方案(包括基于蛋白酶体抑制剂的方案)的SRE风险相似。这些结果突出了持续监测和管理MM相关骨病的重要性。